Trinity Biotech has announced a strategic partnership with Latch Medical to integrate its CGM+ wearable biosensor with Latch's intradermal drug delivery technology.
The collaboration aims to leverage Latch Medical's Pharma Latch platform, which utilizes hollow microneedles for precise and reliable drug administration. This innovative technology is designed for both clinical and home use, allowing for the delivery of various injectable therapies. The partnership seeks to develop tailored therapeutic solutions for conditions like diabetes and obesity by combining the data from Trinity's AI-driven CGM+ system with Latch's drug delivery capabilities.
Trinity Biotech's CGM+ platform, launched in July 2025, integrates multi-sensor data and real-time analytics, positioning it as a potential leader in the evolving landscape of AI-enhanced healthcare. The company plans to initiate a pivotal trial later this year, with regulatory submissions following. The collaboration will explore how real-time metabolic data can optimize therapy, paving the way for more personalized treatment strategies.
This partnership highlights a growing trend in life sciences where advanced biosensing technologies are paired with innovative drug delivery systems. By investing in Latch Medical, Trinity Biotech is signaling its commitment to advancing metabolic health solutions that prioritize personalized care and improved patient outcomes.